TAKEDA-PHARMACEUTICAL
Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced that the company will implement three CSR programs focusing on solutions to maternal and child healthcare problems in Africa and Asia. These programs are implemented to addressing critical issues in maternal and child health in medium- to long-term perspectives, in partnership with international NGOs with a proven track record: World Vision Japan, Save the Children Japan, and Plan International Japan.
Starting from fiscal year 2016, Takeda has been focusing on prevention for health in developing and emerging countries, as a priority theme in its CSR activities. The contents of these programs are in line with our priority theme and will also contribute to helping achieve “Goal 3: Ensuring healthy lives and promoting the well-being for all at all ages” of the Sustainable Development Goals (SDGs)* adopted by the United Nations General Assembly in 2015.
• Project Outline and Implementing Organizations |
||||||||||
Partner | Program outline | Area | Period | Budget | ||||||
1 |
World Vision |
Community Health Worker |
India, Bangladesh, |
5 years |
Approx. |
|||||
2 |
Save the |
Maternal and Newborn Health |
Myanmar, Vietnam, |
5 years |
Approx. |
|||||
3 |
Plan |
Digital Birth Registration | Kenya | 3 years |
Approx. |
|||||
As a pharmaceutical company committed to improving people’s lives, Takeda strives better health for people worldwide through leading innovation in medicine. At the same time, the company will continue to contribute to society by supporting patients and their families who cannot be sufficiently supported by the provision of pharmaceutical products alone.
* |
Sustainable Development Goals (SDGs): International goals for sustainable development included in the “2030 Agenda for Sustainable Development” adopted by the United Nations in September 2015. SDGs consist of 17 goals and 169 targets. http://www.un.org/sustainabledevelopment/sustainable-development-goals/ |
Overview of the Programs by Partner |
|||||
1. |
World Vision Japan: Community Health Worker Training for Maternal and Child Health |
||||
• Overview |
: | In Southern Asia which has a high infant mortality rate compared with other regions, this program will build the capacity of 1,400 community health workers to reduce preventative death among mothers and children by providing some 500,000 people with knowledge and services related to healthcare over five years. | |||
• Regions |
: | India, Bangladesh, Nepal and Afghanistan | |||
• Period |
: | 5 years | |||
• Budget |
: | Approx. ¥500 million | |||
2. |
Save the Children Japan: Maternal and Newborn Health for Ethnic Minorities |
||||
• Overview |
: | This program aims to improve the access and quality of health care for minority populations in Asia. Working in close collaboration with the relevant health authorities, the program will provide health education, training, and services over five years, to 150,000 local residents which include 40,000 ethnic minority women and children, and health care providers | |||
• Regions |
: | Myanmar, Vietnam and Laos | |||
• Period |
: | 5 years | |||
• Budget |
: | Approx. ¥250 million | |||
3. |
Plan International Japan: Digital Birth Registration |
||||
• Overview |
: | Takeda supports efforts to introduce digital birth registration in rural areas in Kenya, where registration rates are low. The program will help to protect children's basic human rights and will contribute to improving healthcare access by providing a system that enables them to receive healthcare services such as immunizations | |||
• Region |
: | Kenya | |||
• Period |
: | 3 years | |||
• Budget |
: | Approx. ¥100 million | |||
About World Vision
Inspired by our Christian values, we are
dedicated to working with the world’s most vulnerable people, especially
with children, World Vision Japan is one of the support offices of World
Vision who works in about 100 countries and is registered with UN ECOSOC.
About Save the Children Japan
Save the Children is an
independent international organization and is a pioneer with one hundred
years of history in the field of child rights. Today, Save the Children
provides support in approximately 120 countries, in partnership with
independent member organizations in 29 countries including Japan to
deliver lasting results for children. Save the Children Japan was
established in 1986.
About Plan International Japan
Plan International is an
independent child rights and humanitarian organization committed to
children living a life free of poverty, violence and injustice. Plan
places a specific focus on girls and women, who are most often left
behind. When disasters or conflict threatens children’s lives and
well-being, Plan is quick to respond. Together, we are transforming
lives.
About Takeda CSR Activities
For Takeda, CSR is rooted in
putting the patient in the center and operating a pharmaceutical
business that creates outstanding products. In addition, we strive to
maintain and improve sound business processes, and to engage in
activities to promote a sustainable society as a good corporate citizen.
In doing so, we are implementing a model of value creation and
preservation through CSR. This will help us to build trust with society,
reinforce our reputation, and further develop the pharmaceutical
business. For more information, visit http://www.takeda.com/csr/policy/
View source version on businesswire.com: http://www.businesswire.com/news/home/20161101006997/en/
Contact:
Media Contacts:
Takeda Pharmaceutical Company Limited
Kazumi
Kobayashi, +81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom